TSE Task Force Bulletin 3
November 15, 2001
Donor Deferral Measures (PDF file)
Prepared by Albert Farrugia, BSc, PhD, on behalf of the
WFH Task Force on TSEs
Policies on donor deferrals made by regulatory bodies such as the FDA differ from country to country. This has led to disharmony in donor screening policies. The table lists the deferral policies in various countries. Please note that the information is subject to change and this should not be regarded as a definitive list.
Revised TSE Task Force Bulletin 2
February 7, 2001; revised November 15, 2001
Variant Creutzfeldt-Jakob Disease and Haemophilia
A Risk Assessment of Plasma-derived Products (PDF file)
Prepared by Albert Farrugia, BSc, PhD, on behalf of the
WFH Task Force on TSEs
The World Federation of Hemophilia’s Task Force on Transmissible Spongiform Encephalopathies (TSEs) has published a revised edition of "Variant Creutzfeldt-Jakob Disease and Haemophilia: A Risk Assessment of Plasma-derived Products". The revised bulletin includes new information on donor deferral measures and the behaviour of the classical CJD agent during factor VIII fractionation processes. The new information highlights the fact that the U.S. Food and Drug Administration (FDA) has acknowledged the ability of plasma fractionation processes, including the techniques used to manufacture FVIII and FIX, to eliminate the agents associated with TSEs. The FDA’s current draft guidance exempts European source plasma donors (with the exception of the U.K. and France) from deferral measures.
TSE Task Force Bulletin 1
September 19, 2001
Blood Transfusion and the Risk of New Variant
Creutzfeldt-Jakob Disease (nvCJD) (PDF file)
By Dr. Bruce Evatt, Member of WFH Executive Committee,
Dr. Paul Giangrande, Vice President Medical
In response to the publication of an article in the Lancet on the report of transmission of BSE by blood transfusion in sheep, Drs. Evatt and Giangrande emphasize that these findings are only a preliminary report and may change when the experiment is concluded. They also assure people with hemophilia that steps have already been taken to minimize or eliminate the risk.
This is intended to provide information only. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. In the case of vCJD and individual medical inquiries, the WFH suggests that further details should be sought from personal doctors or hemophilia centre staff.
|
